Is there an age cutoff where you consider the risks of monoclonal antibody therapy outweigh any potential benefit(s) in early-onset dementia?  

Is there an age cutoff where you consider the risks of monoclonal antibody therapy outweigh any potential benefit(s) in early-onset dementia? Anthony B. Joseph, MD Neuropsychiatrist, McLean Hospital, Harvard Medical School A brief discussion of dementia terminology is worthwhile to avoid confusio...